Contrast-induced nephropathy

7 papers study it5 findings

Interventions

Caloric restriction

downin rats1

1 study

Caloric restriction protects against contrast-induced nephropathy in rats.
“We found that CR was protective of CIN, assessed by renal structure and function.”
Animalsin rats with contrast-induced nephropathy40% reduced food intake4 weeks prior to iopromide administration
Calorie Restriction Protects against Contrast-Induced Nephropathy via SIRT1/GPX4 Activation
Oxidative medicine and cellular longevityOct 19, 2021

Acetylcysteine

downin humans3OR 0.46

3 studies

Acetylcysteine lowers the risk of contrast-induced nephropathy in humans (7.5% vs 14.6%, aOR 0.305 (95% CI 0.097-0.960)).
“The adjusted odds ratio was 0.305 (95% confidence interval: 0.097 to 0.960, p=0.042).”
Human trialintravenous600 mgn = 209
N-acetylcysteine for the prevention of contrast-induced nephropathy in the emergency department
Internal medicine (Tokyo, Japan)Oct 1, 2012
Acetylcysteine lowers the risk of contrast-induced nephropathy in humans (OR 0.46 (95% CI, 0.33-0.63)).
“revealed an odds ratio of 0.46 (95% confidence interval [CI], 0.33-0.63) for the occurrence of contrast-induced nephropathy with the use of high-dose N-acetylcysteine.”
Human trialdaily dose > 1200 mg or single periprocedural dose > 600 mg67.8% malesn = 1,677
High-dose N-acetylcysteine for the prevention of contrast-induced nephropathy
The American journal of medicineSep 1, 2009
Acetylcysteine lowers the risk of contrast-induced nephropathy in humans (RR 0.68 (95%CI, 0.46-1.01)).
“In meta-analysis of the 13 trials, which included 1892 patients, the RR was 0.68 (95%CI, 0.46-1.01).”
Human trialin patients with impaired renal function undergoing coronary angiographyn = 1,892
N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials
American heart journalJan 1, 2006